UC trial compares omega-3 supplements for elderly adults at risk for dementia
National Institute on Aging grant funds first-of-its-kind study
Prior to the onset of Alzheimer’s disease (AD), there is a prolonged period that provides a window of opportunity to slow or prevent disease progression. Unfortunately, few cost-effective and well-tolerated long-term early interventions are currently available.
A new University of Cincinnati trial will compare two types of omega-3 supplements as candidate interventions for elderly adults at risk for dementia. UC’s Robert McNamara, PhD, and Robert Krikorian, PhD, are leading the study, funded by a five-year, $2.2 million grant from the National Institute on Aging.
Study background
Robert McNamara, PhD. Photo/University of Cincinnati.
McNamara’s research has focused on understanding the effects of dietary bioactive lipids on human health and disease, specifically essential fatty acids enriched in the brain that decline with age, like the omega-3 docosahexaenoic acid (DHA).
“Correcting age-related reductions in brain DHA levels represents a plausible strategy to slow or prevent neurodegenerative processes associated with dementia,” said McNamara, director of the Lipidomics Research Program and professor in the Department of Psychiatry and Behavioral Neuroscience in UC’s College of Medicine. “Fish is a primary dietary source of lysophosphatidylcholine-bound DHA (LPC-DHA), and greater fish consumption by elderly adults has been shown to reduce the risk for developing dementia and AD by 30% to 50%.”
Fish oil supplements are widely available as an alternative to eating more fish and are purported to have the same effects, but McNamara said these supplements contain a different kind of DHA called triglyceride-bound DHA (TAG-DHA).
“Recent evidence indicates that TAG-DHA has very limited entry into the central nervous system and instead accumulates in peripheral tissues, whereas LPC-DHA is significantly more effective for increasing brain DHA levels,” he said.
The effects of LPC-DHA supplements have never been investigated, but newly available capsules enriched with LPC-DHA provide a novel opportunity to learn about its effects and address this knowledge gap.
Trial details
In the first-of-its-kind trial, 153 adults who are between 62 and 80 years old and experiencing mild cognitive decline will be randomized to take either a placebo, standard fish oil supplements with TAG-DHA, or new supplements with LPC-DHA for 24 weeks. Participants will provide blood and cerebrospinal fluid (CSF) samples and complete cognitive assessments at the beginning of the study and at week 24 of the study.
Researchers will primarily focus on the impact of DHA levels in CSF samples but will also measure levels of neurodegenerative biomarkers within CSFu.
“We predict that LPC-DHA supplementation will produce greater increases in CSF DHA levels compared with either TAG-DHA or placebo,” he said. “We also predict that LPC-DHA will produce greater positive changes in neurodegenerative biomarker levels compared with TAG-DHA or placebo.”
Additionally, the team will investigate whether changes in CSF DHA levels correlate with improvements in objective measures of executive functioning such as planning and problem-solving and episodic memory performance.
“Collectively, these results are anticipated to provide novel proof-of-concept evidence in support of future LPC-DHA research in aging at-risk adults,” McNamara said.
For more information on the trial, please contact Dawn Skirpan at skirpadn@ucmail.uc.edu or call 513-558-8621.
Innovation Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number 1R01AG084834-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Featured photo at top of omega-3 supplements. Photo/Brett Hondow/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.